IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 16, Issue 9 Ver. II (Sep. 2017), PP 81-88 www.iosrjournals.org DOI: 10.9790/0853-1609028188 www.iosrjournals.org 81 | Page Safety And Efficacy of Unani Compound Drug in Helicobacter Pylori Positive Antral Gastritis (Warm-E-Meda Patients): A Controlled Study *Rahida Hilal (1) , Mehjabeen Fatimah (2) , Anis Ismail (1) , Iqbal Aziz (1) , Tafseer Ali (1) Department Of Jarahat, A. K. Tibbiya College, A. M. U., Aligarh, Uttar Pradesh, India. National Institute In Unani Medicine, Bangalore, Karnataka, India. Corresponding Author - Rahida Hilal Abstract: Warm-e-meda/gastritis is the prime concern in unani medicine and unani physicians emphasized on better functioning of stomach/meda. Acute gastritis, chronic gastritis, peptic ulcer disease, atrophic gastritis, gastric carcinoma, primary gastric B-cell lymphoma are some of the manifestation of H. pylori infection. An appreciable number of unani mufrad (single) and murakkab (compound) drugs are used to treat them. In this study we evaluate the efficacy of a unani compound drug in endoscopically proved H.pylori positive antral gastritis. This was a double blind randomised clinical trial, on 160 patients. All the patients were divided into three groups. Test group comprising of 110 patients, control group comprised of 20 patients and placebo group comprising 30 patients. Patients of control group were given tab Pantoprazole (40 mg). All the drugs were given for a period of 3 months and weekly follow up was done and repeat endoscopy was carried out after completion of treatment. In 84.5% patients H. Pylori positive antral gastritis was found in group A (test group), 66.7% in group B (Placebo group) and 100% in group C (control group). Antral gastritis was cured in 89.1% patients in group A (test group), only 3.3% in group B and 40% in group C. 90% patients became H. Pylori negative after receiving test drug for 3 months, only 6.7% patients became negative in group B while in group C all the patients remained H. Pylori positive after treatment. In our study we found the Unani polyherbal formulation was found to be effective in treating antral gastritis and eradicating H. Pylori bacteria. Keywords: Antral gastritis, Endoscopy, H. pylori. --------------------------------------------------------------------------------------------------------------------------------------------------- Date of Submission: 22 -08-2017 Date of acceptance: 09-09-2017 -------------------------------------------------------------------------------------------------------------------------------------------------- I. Introduction Antral gastritis (warm-e-meda) is one of the commonest problem among different culture and civilizations. Unani physicians have mentioned the disease by different names e.g Hurqat-e-Meda, Sozish-e-Meda, Warm-e-Meda, and Iltehab-e-Meda. They described gastritis on the basis of clinical features (Warm-e-meda har, Warm-e meda barid), causative factors and humor (Warm-e-meda damvi, Warm-e-meda safravi, Warm-e-meda balghami, Warm-e-meda saudavi), duration (Warm-e-meda falghamuni, Warm-e-meda hamratemedi, Warm-e- meda rekhu, Warm-e-meda sulb) and gross pathological changes (Warm-e-meda ha’ad (acute gastritis), Warm-e- meda muzmin (chronic gastritis). There is a close relationship between chronic gastritis and H. Pylori infection was reported and about 75% patients with chronic gastritis have H. Pylori infection compared to10% in those without gastritis. (1) Dr Berry and Warren discovered H. Pylori in 1882 in patients having gastritis and gastric ulcers, since then H. Pylori has been the focus of researchers. (2) H. Pylori infection once established persists throughout life and generally remains asymptomatic in many cases. The rate of infection increases with age and its prevalence is related to the stage of social development of the people. (3) More than 50% of world’s population harbours H. Pylori in the GIT. The infection is more prevalent in developing countries like India (80%) as compared to western countries. (4,5) Infection of H. Pylori spread either by eatables, fomite, through direct contact or by vectors, exact route of transmission is not known but it may be transmitted through Oro-oral route, Gastro- oral route, Faeco-oral route and also transmits from one patient to another by inadequately disinfected endoscope. (6) Chief complaints of patient includes abdominal pain, dyspepsia, indigestion, nausea or vomiting, heart burn, loss of appetite. Initially the disease starts as superficial gastritis, eventually it may progress to atrophic gastritis or gastric carcinoma. Other infestations caused by H. Pylori infection includes peptic ulcer disease, Primary gastric B cell lymphoma, iron deficiency anaemia and B12 deficiency. (7-10)